Want to see AU:OSL full AI Analyst Report?
Top Page
OncoSil Medical Ltd
(Sydney:OSL)
Select Model
Select Model
Rating:49Neutral
Price Target:
AU$0.67
▼(-30.72% Downside)
Action:Reiterated
Date:06/23/26
The score is held down primarily by weak financial performance, with persistent losses and negative operating/free cash flow outweighing the benefit of revenue growth and low leverage. Technicals are supportive short-term (price above key moving averages, positive MACD) but appear overbought (high RSI/Stoch), adding near-term risk. Valuation is constrained by negative earnings (negative P/E) and no dividend yield data.
Positive Factors
Targeted device with focused indication
OncoSil’s business is anchored on a differentiated medical device focused on locally advanced pancreatic cancer. A niche, procedure-driven therapy creates high clinical barriers to entry, supports durable adoption by specialist centers, and aligns revenue with procedural volume rather than commodity pricing.
Negative Factors
Persistent unprofitability and weak margins
Negative gross and operating margins indicate the core business currently does not generate unit economics sufficient to cover costs. Without sustained margin improvement through pricing, scale, or cost reduction, losses will pressure cash needs and hinder long-term viability.
Read all positive and negative factors
Positive Factors
Negative Factors
Targeted device with focused indication
OncoSil’s business is anchored on a differentiated medical device focused on locally advanced pancreatic cancer. A niche, procedure-driven therapy creates high clinical barriers to entry, supports durable adoption by specialist centers, and aligns revenue with procedural volume rather than commodity pricing.
Read all positive factors
OncoSil Medical Ltd (OSL) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$20.85M
Dividend YieldN/A
Average Volume (3M)24.03K
Price to Earnings (P/E)―
Beta (1Y)1.56
Revenue Growth68.30%
EPS Growth40.74%
CountryAU
Employees6
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-0.95
Shares Outstanding30,888,899
10 Day Avg. Volume8,764
30 Day Avg. Volume24,029
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)4.23
Price to Sales (P/S)11.20
P/FCF Ratio-1.09
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
OncoSil Medical Ltd Business Overview & Revenue Model
Company Description
OncoSil Medical Limited, a medical device company, develops and commercializes localized radiation therapy for the treatment of pancreatic and distal cholangiocarcinoma. The company’s lead product is OncoSil, a single-use brachytherapy device for ...
How the Company Makes Money
null...
OncoSil Medical Ltd Financial Statement Overview
Summary
Income Statement
25
Negative
Balance Sheet
30
Negative
Cash Flow
20
Very Negative
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.33M | 1.17M | 516.63K | 367.68K | 231.79K | 213.07K |
| Gross Profit | -3.94M | -1.08M | -993.00K | -1.22M | -6.73M | -748.00K |
| EBITDA | -15.34M | -15.06M | -12.91M | -11.17M | -11.41M | -11.31M |
| Net Income | -12.92M | -15.10M | -11.91M | -11.34M | -10.73M | -10.43M |
Balance Sheet | ||||||
| Total Assets | 7.13M | 7.15M | 6.72M | 11.47M | 13.07M | 14.15M |
| Cash, Cash Equivalents and Short-Term Investments | 2.85M | 5.11M | 4.50M | 9.39M | 11.28M | 12.24M |
| Total Debt | 42.47K | 69.92K | 70.67K | 170.81K | 304.21K | 484.37K |
| Total Liabilities | 3.29M | 4.04M | 1.98M | 1.59M | 1.91M | 2.45M |
| Stockholders Equity | 3.84M | 3.10M | 4.74M | 9.88M | 11.16M | 11.70M |
Cash Flow | ||||||
| Free Cash Flow | -12.91M | -12.08M | -11.02M | -11.37M | -10.12M | -8.87M |
| Operating Cash Flow | -12.91M | -12.06M | -10.82M | -11.32M | -10.11M | -8.82M |
| Investing Cash Flow | -6.56K | -14.96K | -197.06K | -57.82K | -5.83K | -54.00K |
| Financing Cash Flow | 7.35M | 12.73M | 6.13M | 9.49M | 9.16M | 111.25K |
OncoSil Medical Ltd Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | AU$20.85M | -0.71 | -372.27% | ― | 68.30% | 40.74% | |
49 Neutral | AU$33.78M | -3.98 | -98.14% | ― | 14.88% | 35.94% | |
45 Neutral | AU$2.49B | -12.87 | -890.76% | ― | -0.80% | -249.48% | |
44 Neutral | AU$140.83M | -12.89 | -70.29% | ― | ― | -62.15% | |
42 Neutral | AU$63.03M | -3.20 | -54.48% | ― | 17.24% | -20.00% | |
40 Underperform | AU$23.94M | -1.77 | -180.06% | ― | 74.74% | 4.32% |
* Healthcare Sector Average
AU:OSL
OncoSil Medical Ltd
0.68
-0.52
-43.42%
AU:CYC
Cyclopharm Limited
0.50
-0.41
-45.05%
AU:MX1
Micro-X Ltd.
0.03
-0.02
-36.00%
AU:EMV
EMvision Medical Devices Ltd.
1.52
-0.23
-12.93%
AU:CBL
Control Bionics Ltd.
0.08
0.05
182.76%
AU:4DX
4DMedical Ltd
4.16
3.92
1633.33%
OncoSil Medical Ltd Corporate Events
OncoSil to Release 41,067 Escrowed Shares Issued as Director Fees
Jun 29, 2026
OncoSil Medical Limited, a specialist in targeted intratumoural radiotherapy for pancreatic cancer, focuses on its CE-marked OncoSil device, which allows higher radiation doses directly into tumours while sparing nearby organs. The company operate...
OncoSil flags FDA progress and early TRIPP-FFX data in investor update
Jun 9, 2026
OncoSil Medical Limited has released an investor presentation and will host a webinar to update investors on recent interactions with the U.S. Food and Drug Administration and to discuss initial results from its TRIPP-FFX clinical trial. The updat...
OncoSil Nears Final FDA HDE Decision for Rare Bile Duct Cancer Device
Jun 9, 2026
OncoSil Medical has reached the final stage of U.S. FDA review for its Humanitarian Device Exemption application for the OncoSil device in distal cholangiocarcinoma, a rare cancer with poor prognosis and limited treatment options. The FDA has conf...
OncoSil Seeks Trading Halt Ahead of Key Trial Results and FDA Update
Jun 3, 2026
OncoSil Medical has requested an immediate trading halt for its securities on the ASX, as the company prepares to release material results from its TRIPP-FFX clinical trial and respond to recent correspondence from the U.S. Food and Drug Administr...
OncoSil on track for TRIPP-FFX data as it targets broader EU approval for pancreatic cancer device
May 31, 2026
OncoSil Medical, a specialist in localised radiation therapy for unresectable locally advanced pancreatic cancer, has developed the OncoSil device to deliver higher, targeted intratumoural doses while limiting exposure to surrounding organs. The c...
OncoSil Seeks ASX Quotation for New Employee Incentive Shares
May 27, 2026
OncoSil Medical has applied to the ASX for quotation of 191,667 new ordinary fully paid shares issued on 26 May 2026. The securities were issued under an employee incentive scheme, indicating continued use of equity-based compensation to reward an...
OncoSil Issues New Unquoted Options Under Employee Incentive Scheme
May 27, 2026
OncoSil Medical Ltd has notified the market of the issue of 687,092 unquoted options under an employee incentive scheme, with a zero exercise price and an expiry date of June 30, 2029. The new options, issued on May 26, 2026, are not intended to b...
OncoSil strengthens governance with new joint company secretary
May 25, 2026
OncoSil Medical Limited, a specialist in interventional oncology devices for unresectable locally advanced pancreatic cancer, markets its CE-marked OncoSil device across over 30 countries, where it enables higher, targeted intratumoural radiation ...
OncoSil gains ASCO spotlight as Spanish data bolster pancreatic cancer device
May 22, 2026
OncoSil Medical has had Spanish multi-centre clinical data on its OncoSil pancreatic cancer device accepted for poster presentation at the 2026 American Society of Clinical Oncology Annual Meeting in Chicago. The study of 51 patients with unresect...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.